Acute Effects of rhBNP in Patients With PH Associated With Acute Exacerbation of Chronic Pulmonary Disease

Pulmonary hypertension (PH) is a descriptive name for abnormally elevated pressures in the pulmonary vasculature, which seriously affects the quality of life and survival of patients. Currently, no effective drugs treatment was used in patients with pulmonary hypertension due to acute exacerbation of lung disease. Recombinant Human Brain Natriuretic Peptide (rhBNP)was approved in 2001 for use in patients with acute heart failure on the basis of studies showing a reduction in pulmonary-capillary wedge pressure(PCWP) and pulmonary arterial pressure (PAP) and improvement cardiac output (CO) . Thus, the study was designed to administer rhBNP as a continuous infusion for 24 hours on pulmonary hypertension of acute exacerbations of chronic pulmonary disease monitoring by Swan- Ganz catheter. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.

Inclusion criteria

• age>18 years old, male or female;
• in acute exacerbation period and with a history of chronic respiratory diseases;
• cardiac ultrasound showed a pulmonary hypertension ≥50mmHg;
• grade II or WHO grade of heart function;
• signed informed consent.

Exclusion criteria

• pulmonary hypertension not associated with chronic lung disease;
• Acute or severe chronic left heart failure;
• severe respiratory failure during receipt of non-invasive or invasive ventilator therapy;
• mPAP≤25mmHg or pulmonary capillary wedge pressure (PCWP) ≥15mmHg at rest as assessed by Swan- Ganz catheter;
• a high risk of hypotension (systolic pressure <100 mmHg or 110 mmHg with the use of intravenous nitroglycerin);
• Uncontrolled arterial hypertension;
• acute coronary syndrome;
• Severe left ventricular hypertrophy;
• Congenital or acquired valvular or myocardial disease;
• end-stage renal disease during receipt of renal replacement therapy;
• clinically significant anemia;
• other contraindications for vasodilators;
• treatment with dobutamine (at a dose ≥5 μg per kilogram of body weight per minute);
• treatment with milrinone or levosimendan within the previous 30 days.